Prostate Cancer Management: Enhancing Cost-Effectiveness and Patient Outcomes A CE/CME Supplement to The American Journal of Managed Care

Published on: 

3.0 Credits - CME/CPE | Expires 12/15/2015

The activity is supported by educational grants from AbbVie Inc, Astellas Scientific and Medical Affairs, Inc, and Janssen Biotech, Inc., and administered by Janssen Scientific Affairs, LLC, and sanofi-aventis US.


Robert Dreicer, MD, MS, FACP, FASCO

Director, GU Medical Oncology

Taussig Cancer Institute

Cleveland Clinic

Cleveland, Ohio

Professor of Medicine

Cleveland Clinic Lerner College of Medicine

Cleveland, Ohio

Deputy Associate Director of Clinical Research

Case Comprehensive Cancer Center

Cleveland, Ohio

Michael Kolodziej, MD, FACP

National Medical Director

Oncology Solutions


Hartford, Connecticut

Neal Shore, MD, FACS

Medical Director

Carolina Urologic Research Center (CURC)

Atlantic Urology Clinics

Myrtle Beach, South Carolina


Activity Overview

Prostate cancer is the most common cancer and the second-leading cause of death among men in the United States. It is associated with significant clinical and economic burden. This supplement is intended to provide a clinical understanding of prostate cancer, discuss current, new, and evolving treatment strategies for early-stage, recurrent, and advanced prostate cancer, and discuss the economic burden of the disease.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the overall cost-effectiveness of treatment strategies for early-stage prostate cancer
  • Ascertain the currently available and investigative treatment options for patients with biochemically recurrent prostate cancer
  • Discuss the rapidly evolving treatment landscape for advanced prostate cancer and the role of new agents

Intended Audience

Managed care clinicians and administrators, including physicians, pharmacists, medical and formulary directors, and other managed care professionals involved in the care of patients with prostate cancer.

Release date: December 15, 2014

Expiration date: December 15, 2015

Estimated time to complete activity: 3.0 hours

Type of activity: Knowledge

Fee: Free

Physician Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accredita­ tion Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Cincinnati designates this journal-based activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Credit

Accreditation Statement

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 3.0 contact hours (0.30 CEUs) under the ACPE universal activity number UAN 0290-9999-14-108-H01-P. The activity is available for CE credit through December 15, 2015.

Obtaining Credit:

Participants must take the pretest, read the journal supplement, and complete the online posttest achieving a passing score of 70% or higher. Once the posttest is submitted each participate will need to complete and submit the online activity evaluation and request their credit before the activity expires on December 15, 2015.

For Physician credit (CME) only

Start Activity

For Pharmacy credit (CPE) only

Start Activity

System Requirements

PC-based participants

Required: Windows® 7, Vista, XP, 2003 Server or 2000

Macintosh®-based participants

Required: Mac OS® X 10.4.11 (Tiger®) or newer

For questions about this Internet CPE activity, please contact:

Privacy Policy and Terms of Use Information: